Cargando…
Immunometabolic Therapeutic Targets of Graft-versus-Host Disease (GvHD)
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a curative option in the treatment of aggressive malignant and non-malignant blood disorders. However, the benefits of allo-HSCT can be compromised by graft-versus-host disease (GvHD), a prevalent and morbid complication of allo-HSCT....
Autores principales: | Mhandire, Kudakwashe, Saggu, Komalpreet, Buxbaum, Nataliya Prokopenko |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8619522/ https://www.ncbi.nlm.nih.gov/pubmed/34822394 http://dx.doi.org/10.3390/metabo11110736 |
Ejemplares similares
-
Chronic GvHD NIH Consensus Project Biology Task Force: evolving path to personalized treatment of chronic GvHD
por: Buxbaum, Nataliya P., et al.
Publicado: (2022) -
Inflammasome effects in GvHD
por: Koehn, Brent H., et al.
Publicado: (2015) -
Editorial: Interferons and GvHD
por: Kim, Boram, et al.
Publicado: (2022) -
Antibody- and aptamer-strategies for GvHD prevention
por: Oelkrug, Christopher, et al.
Publicado: (2015) -
Established and Emerging Treatments of Skin GvHD
por: Link-Rachner, Cornelia S., et al.
Publicado: (2022)